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Abstract 
Hyperthyroidism is the most common endocrinopathy of geriatric cats and has 
physiologic effects on almost every organ in the body.  It specifically affects the kidneys by 
increasing renal blood flow and glomerular filtration rate.  In addition, activation of the renin 
angiotensin aldosterone system (RAAS) is increased and ultimately leads to efferent glomerular 
arteriole constriction and potentially glomerular hypertension.  The classic treatment modalities 
for feline hyperthyroidism (anti-thyroid medication, radioiodine or surgery) have been evaluated 
for their overall effects on renal function.  Studies have demonstrated that glomerular filtration 
rate (GFR) declines and serum creatinine increases with hyperthyroid treatment independent of 
the treatment modality.  Hill’s® Prescription Diet® y/d® Feline, a relatively new dietary treatment 
modality for feline hyperthyroidism with controlled iodine concentrations, reduced phosphorus 
and protein, and increased omega-3 fatty acids, has been shown to significantly decrease thyroid 
hormone levels.  The research provided in this report is the first evaluating the posttreatment 
effects of y/d® Feline on renal function.   In agreement with previous studies, our research found 
that y/d® Feline resulted in a significant decrease in thyroid hormone levels.  However, in 
contrast to other treatment modalities, y/d® Feline did not result in a significant decline in GFR, 
and it did result in a significant decline in mean serum creatinine concentration.  These data 
indicate that y/d® Feline, as a treatment for feline hyperthyroidism, does not have a negative 
effect on renal function. 
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Chapter 1 - Current Perspectives of Feline Hyperthyroidism 
 Feline Hyperthyroidism Introduction 
The clinical condition of feline hyperthyroidism occurs due to excessive production and 
secretion of thyroid hormones thyroxine (T4) and triiodothyronine (T3).  Hyperthyroidism was 
first described in human beings in 1913, and in cats in 1979.1  Most hyperthyroid cats (70%) 
have benign adenomatous disease of both thyroid glands,2 and a minority (<5%) have a 
malignant thyroid carcinoma.3  
 Etiology of Feline Hyperthyroidism 
The etiology of feline hyperthyroidism remains incompletely understood.  Due to the 
increasing prevalence of feline hyperthyroidism since the syndrome was first identified, the 
possible contributions of immunologic, nutritional, environmental, and genetic factors have been 
extensively evaluated.  In human beings, hyperthyroidism is typically associated with 
autoimmune disease (Graves’ disease), and a similar etiology has been investigated in cats.  
Although some hyperthyroid cats have been found to have autoantibodies mimicking thyroid 
stimulating hormone (TSH) that may contribute to the development of hyperthyroidism,4 other 
investigators have not been able to verify this finding.5,6  Other studies have suggested an 
increased prevalence of hyperthyroidism in cats fed mostly canned food, or specifically canned 
foods with fish or liver and giblets-flavors.7,8,9,10  Environmental factors that have been 
implicated include soy isoflavones, phthalates, resorcinol, polyphenols and polychlorinated 
biphenyls, some of which are considered goitrogens and others of which can be found in the 
environment or commercial cat foods.11,12  Additionally, cats that live primarily indoors, and 
those that have regular exposure to flea sprays, fertilizers, pesticides, or insecticides have been 
found to have an increased prevalence of hyperthyroidism, while Siamese, Himalayan and 
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purebred cats have been reported to have a decreased risk for hyperthyroidism.7,10,11  A direct 
cause and effect between the above factors and the development of hyperthyroidism remains 
difficult to prove. 
 
 Clinical Presentation of Feline Hyperthyroidism 
Cats that are affected by hyperthyroidism have a mean age of 12-13 years old, with less 
than 5% being less than 10 years of age.13  The prevalence of hyperthyroidism in a population of 
cats greater than nine years of age was recently reported to be 6%.14  The diagnosis of feline 
hyperthyroidism involves consideration of clinical signs, physical exam findings, as well as 
clinicopathologic changes and specific confirmatory testing.  Because thyroid hormones have 
multiple actions throughout the body, almost every organ system is affected by elevations in 
thyroid hormone concentrations.  Classically, cats that exhibit clinical evidence of thyrotoxicosis 
have a history of weight loss in the face of a normal or increased appetite, increased 
activity/restlessness, polyuria/polydipsia, unkempt hair coat, and gastrointestinal signs such as 
vomiting and diarrhea.2,13,15,16  However, the severity of reported signs have decreased in the past 
20 years as the syndrome is recognized earlier in the course of disease, presumably due to 
increased awareness. 2,13,15,16  In addition, approximately 10% of affected cats will exhibit so-
called ‘apathetic hyperthyroidism’, which is characterized by decreased appetite and lethargy.2,15  
More than 90% of hyperthyroid cats have a palpable thyroid nodule at the time of diagnosis.  
Elevation in thyroid hormone concentration also causes alterations in cardiovascular 
hemodynamics, affecting heart rate, heart rhythm and cardiac output.16,17,18  In hyperthyroid cats 
this can be appreciated clinical by the presence of tachycardia, increased heartbeat intensity, and 
arrhythmias as well as a systolic heart murmur (usually grade I-III/VI), which occurs in 
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approximately 50% of hyperthyroid cats.2,13,15  Although these may be common findings on 
physical exam, congestive heart failure is less common.2,13  Finally, mild to moderate 
hypertension was originally thought to be a common finding in hyperthyroid cats, which would 
resolve with return to a euthyroid state.  Current reports indicate that approximately 10% of cats 
are reported to have hypertension at the time of diagnosis of hyperthyroidism,19 which is 
associated with a reduced survival time in affected cats.20  An additional 20% of cats develop 
hypertension following treatment and return to a euthyroid state, which may be associated with 
the unmasking of renal dysfunction.19,21 
Hematologic and biochemical abnormalities are common with hyperthyroidism.  
Approximately 40-50% of cats with hyperthyroidism exhibit slight elevations of the packed cell 
volume (PCV), and approximately 20% develop a macrocytosis.2,13  Erythrocyte changes are 
thought to result from an increase in erythropoietin production secondary to the increase in 
oxygen consumption that occurs in hyperthyroidism, as well as the direct effect on the bone 
marrow by thyroid hormone-mediated β-adrenergic stimulation to increase production and 
release of red blood cells.22  Common leukogram changes include neutrophilia, lymphopenia, 
eosinopenia, and monocytosis.13,15  The most common biochemical changes observed in 
hyperthyroid cats are increased activities of  aminotransferase (ALT) and alkaline phosphatase 
(ALP).  In fact, greater than 90% of hyperthyroid cats have an elevation in either ALT or 
ALP.2,13,15  Although elevations in both ALT and/or ALP are typically mild, severe elevations 
can be observed.  There is little data regarding the mechanism for liver enzyme elevations in cats 
with hyperthyroidism, however, in hyperthyroid rats, a direct toxic effect of T3 resulted in lipid 
peroxidation, protein oxidation, and glutathione depletion of hepatic mitochondria with 
subsequent apoptosis has been observed.23,24  Limited feline studies have shown that both the 
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liver and bone ALP isoenzymes contribute to serum ALP elevations in hyperthyroid cats.25,26,27  
Although previous recommendations included evaluating hyperthyroid cats with ALP or ALT 
activities greater than 500 IU/L for concurrent disease,2,13,15 further investigation has revealed 
that the changes experienced by the liver secondary to hyperthyroidism usually do not affect 
liver function tests, such as paired serum bile acids, and thus such testing may not be 
warranted.28  In addition, histologic evaluation of liver samples from cats with hyperthyroidism 
reveal nonspecific and mild changes, and liver enzyme changes associated with hyperthyroidism 
usually return to within the reference interval with successful management of hyperthyroidism.29   
Urinalysis results of hyperthyroid cats are generally nonspecific, however many 
hyperthyroid cats have mild proteinuria.  Although the mechanism of proteinuria in hyperthyroid 
cats is incompletely understood, successful treatment of hyperthyroidism leads to a decrease in 
urinary protein excretion as assessed by urine protein to urine creatinine (UPC) ratio.30  It has 
also been reported that up to 12-22% of hyperthyroid cats present with urinary tract 
infections.31,32  When signalment, history, clinical signs, physical exam findings, and initial blood 
screenings are compatible with feline hyperthyroidism, additional confirmatory testing is 
recommended. 
 
 Specific Thyroid Function Tests  
 Total T4 Concentration 
Although T3 is the biologically active form of thyroid hormone, T4 is the primary 
hormone secreted from the thyroid gland and found in the circulation and is later metabolized to 
T3 in peripheral tissues.33,34  Although total T4 (TT4) concentrations vary considerably throughout 
the day in hyperthyroid cats, more than 90% of hyperthyroid cats will be confirmed via random 
  5 
serum TT4 testing.13,15,35  In contrast, over 25% of hyperthyroid cats will have a serum total T3 
(TT3) concentration within the reference interval.13,35  Thus, measurement of circulating serum 
TT4 concentration is superior to measurement of serum TT3 concentration for identifying cats 
with hyperthyroidism, and is the initial screening test of choice.15,36,37  Furthermore, simultaneous 
measurement of TT3 and TT4 concentrations does not offer a diagnostic advantage over TT4 
measurement alone.13,35,37 
Serum TT4 concentration measures the protein-bound and free hormone fractions.  T4 is 
highly protein bound and the free (unbound) fraction makes up less than 1% of the circulating 
pool.  Radioimmunoassay (RIA) is the gold standard method for measurement of serum TT4, but 
methodology limitations associated with RIA has prompted validation of other assay methods 
including a homogenous enzyme immunoassay and chemiluminescent enzyme immunoassay 
(CLEIA).35,38,39,40  The availability of these methods varies based on the laboratory used.  In 
addition, a commercial semiquantitative ELISA T4 kit is available for in-house use.  The ELISA 
method has the advantage of providing instant results to the practitioner, and is accurate when 
compared to the RIA method.40  Overall, each of these tests has pros and cons; the test chosen 
should be based on the turn around time needed and test availability. 
Due to fluctuations of thyroid hormones in the circulation, the TT4 concentration of cats 
with early or mild hyperthyroidism may fall within the reference interval.  Furthermore, certain 
drugs and non-thyroidal disorders can suppress total thyroid hormone concentrations.  
Mechanisms for TT4 suppression include altered thyroid hormone metabolism, altered T4 binding 
within cells or to plasma carrier proteins, and altered transport of T4 into cells.41  Of hyperthyroid 
cats with the TT4 concentration within the reference interval, approximately 20-30% have 
concurrent illness and the remaining 70-80% likely have early disease.35  Thus, if a single, 
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random serum TT4 concentration is within the reference interval, yet the cat has historical, 
physical exam, and laboratory changes compatible with hyperthyroidism, the TT4 concentration 
should be reevaluated after several weeks, in addition to ruling out and/or treating any 
nonthyroidal illness.38  If non-thyroidal illness has been ruled-out and a repeat TT4 remains 
within the reference interval, performing a serum free T4 (fT4) assay is recommended. 
 
 Free T4 Concentration 
Serum fT4, the unbound fraction of T4 hormone, represents less than 1% of total 
circulating thyroid hormone.  FT4 is the only T4 fraction that can diffuse across cell membranes 
and serves as a “prohormone” for T3.34  Serum fT4 is a more sensitive test for hyperthyroidism 
than the serum TT4.  Greater than 95% of hyperthyroid cats that have a TT4 concentration within 
the reference interval will have an elevated fT4 concentration.35  It is generally accepted that cats 
without non-thyroidal illness that have a TT4 concentration in the upper third of the reference 
interval, an elevated fT4 concentration and compatible clinical signs, are likely hyperthyroid.42  
fT4 concentration is also affected by non-thyroidal factors, which can cause a false elevation in 
fT4.  The mechanism for elevation of circulating fT4 during nonthyroidal disease is not 
completely known, but has been speculated to be due to impaired clearance of fT4 from the 
serum33.  Up to 12% of euthyroid cats may have an elevated fT4 concentration due to 
nonthyroidal illness, making measurement of fT4 less specific for hyperthyroid diagnosis than 
TT4.35,41,43  For this reason, fT4 should not be used as the sole test for the diagnosis of 
hyperthyroidism.  Finally, hyperthyroid cats with an elevated TT4 concentration will always have 
a concurrent elevation in the fT4 concentration.  Therefore, measurement of fT4 is not indicated 
or necessary if the TT4 is elevated.35  If TT4 and fT4 concentrations are found within the 
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reference interval on several separate occasions, but clinical suspicion of hyperthyroidism 
remains high, additional testing (e.g. T3 suppression test, thyrotropin-releasing hormone (TRH) 
stimulation test, thyroid-stimulating hormone (TSH) response test, thyroid scintigraphy) should 
be considered.  
 
 T3 Suppression Test 
The T3 suppression test evaluates the integrity of the physiological feedback loop by 
which thyroid hormone regulates pituitary gland function.  In normal cats, thyroid hormone 
exerts negative feedback on the hypothalamus and anterior pituitary and leads to decreased 
secretion of TRH and TSH, respectively, until inhibition is released by a fall in circulating 
thyroid hormone concentrations.  The T3 suppression test works according to the principle that 
administration of exogenous T3 to a cat with normal thyroid function suppresses pituitary TSH 
secretion and leads to a decrease in endogenous T4 secretion.  Cats with primary 
hyperthyroidism, however, secrete thyroid hormones independent of pituitary control.  In 
contrast with normal cats, TSH secretion is chronically suppressed during primary 
hyperthyroidism and exogenous T3 administration has little to no effect on endogenous serum 
TT4 concentrations.  The T3 suppression test is helpful in distinguishing mildly hyperthyroid cats 
from euthyroid cats; however, it requires multiple days of treatment for suppression to occur and 
owner compliance is critical.  Following collection of baseline serum TT3 and TT4 samples, 
owners are instructed to administer T3 hormone (liothyronine; Cytomel) at 25µg orally three 
times daily for two days, and once on the morning of day 3, for a total of 7 doses.44  Two to four 
hours after the final dose is given, TT3 and TT4 concentrations are assessed.  The pre- and post-
liothyronine samples should be submitted to the laboratory at the same time to limit the influence 
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of interassay variation.  Cats with hyperthyroidism will have little to no decrease in TT4 
concentration after liothyronine administration, while suppression of TT4 concentration of 50% 
or more will occur in euthyroid cats.44  Lack of TT4 suppression could also be due to poor 
compliance with the testing protocol, which can lead to a false positive result.  Compliance can 
be gauged by comparing TT3 concentrations before and after the test.  If the liothyronine was 
administered correctly, the final TT3 concentration will be elevated above the initial sample.  If 
this does not occur, owner compliance should be questioned, and the test result should be 
considered invalid.   
 
 TRH-Stimulation Test 
The TRH-stimulation test also evaluates the integrity of the pituitary-thyroid gland 
feedback system via administration of TRH.  TRH from the hypothalamus stimulates release of 
TSH from the anterior pituitary gland to increase synthesis and release of thyroid hormones from 
the thyroid gland.  Administration of exogenous TRH to cat with normal thyroid function will 
increase TSH secretion and increase serum TT4 concentrations.  To perform a TRH-stimulation 
test, a serum TT4 sample is collected before and 4 hours after intravenous administration of 
0.1mg/kg TRH.45  Cats with even mild hyperthyroidism should have little (<50%) or no increase 
in serum TT4 concentration due to hyperthyroid-induced chronic suppression of endogenous 
TSH.   Clinically healthy cats, and cats with nonthyroidal disease should have an increase in 
serum TT4 concentrations of greater than 60%.45  This test is considered as reliable as a T3 
suppression test, however, the only FDA-approved preparation of TRH is no longer available, 
side effects are common following TRH administration,45 and results can be difficult to 
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determine especially in cats with concurrent illness,46 thus, generally this test is not 
recommended. 
 
 TSH-Response Test 
A TSH-response test is typically utilized to aid in the diagnosis of hypothyroidism in 
dogs, but has the potential to differentiate euthyroid cats from those with hyperthyroidism as 
well.  The protocol involves obtaining a baseline serum TT4 value, followed by administration of 
TSH, and measure of TT4 6-8 hours later.  Hyperthyroid cats should have little or no response to 
exogenous TSH administration, however, results can be difficult to interpret due to overlap in 
TT4 response in euthyroid and hyperthyroid cats.29,37,41  In addition, the bovine TSH initially 
utilized for this test is no longer available, and the response to administration of recombinant 
human TSH has not been evaluated in hyperthyroid cats.  Therefore, this test is not currently 
recommended for the diagnosis of hyperthyroidism.29,37,41  
 
 Random TSH Concentration Testing 
Measuring a random circulating TSH concentration to detect subclinical hyperthyroidism 
may be a helpful tool.  Cats with subclinical hyperthyroidism should have a low circulating TSH 
concentration before elevation in TT4 occurs.14  When evaluating hyperthyroid cats, normal cats, 
and cats with CKD, it was found that all hyperthyroid cats had TSH values below the 
quantification value.41  However, 5 out of 40 non-hyperthyroid cats also had TSH levels below 
the quantification value, but the presence of CKD did not appear to affect TSH concentrations.41   
Furthermore, in 104 client-owned cats, TSH concentrations were evaluated with the hypothesis 
that euthyroid geriatric cats with undetectable TSH concentrations would have an increased risk 
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of developing clinical hyperthyroidism.14  Although the cats with undetectable baseline TSH 
concentrations were significantly more likely to be diagnosed with hyperthyroidism within 14 
months, only about half of the cats with undetectable baseline TSH concentrations became 
hyperthyroid within the 14-month study period.14  Ultimately, further studies are needed to 
determine the diagnostic utility of a random TSH concentration in cats. 
 
 Thyroid Scintigraphy 
If results of thyroid hormone tests are equivocal but clinical suspicion remains high, 
thyroid scintigraphy should be considered to confirm hyperthyroidism.  In addition to confirming 
hyperthyroidism, thyroid scintigraphy can also provide information that aids in treatment 
decisions, and is the best way to detect metastasis of malignant thyroid tumors.  Multiple 
radionuclides have been utilized for imaging the thyroid glands.  The use of radioactive iodine 
(131I, or 123I) has been described, however radioactive technetium-99m (pertechnetate; 99mTcO4) 
is the radionuclide most commonly used.  99mTcO4 is trapped and concentrated within thyroid 
follicular cells because 99mTcO4 molecular configuration mimics the size and charge of iodide.47  
99mTcO4 is the radionuclide of choice for routine thyroid imaging due to its low-cost, short half-
life, rapid uptake by the thyroid, low-energy γ-particle emission, and lack of β-emission.47  After 
IV injection, 99mTcO4, concentration within the thyroid tissue occurs over 20-120 minutes and all 
functioning thyroid tissue can be detected using a gamma camera.2,47,48,49  In normal cats, 
99mTcO4 concentrates in salivary and thyroid tissue to a similar degree and to a lesser degree in 
epithelial tissues such as the gastric mucosa.47  The normal thyroid glands are elongate ovals of 
similar size and location.  Thyroid activity is assessed by comparing the ratio of 99mTcO4 uptake 
by the thyroid gland with uptake by the zygomatic-molar salivary gland using a region of interest 
  11 
drawn to include salivary and thyroid tissue.  The thyroid: salivary gland uptake ratio is 
approximately 1: 1 in normal cats and greater than 1:1 in hyperthyroidism.47,48  The increase in 
thyroid: salivary ratio is directly proportional to thyroid gland function.48 
As previously discussed, most hyperthyroid cats have bilateral disease, even if not 
appreciated with thyroid palpation.  Thyroid scintigraphy allows the extent of abnormal thyroid 
tissue to be determined.  Scintigraphy of cats with true unilateral thyroid disease will reveal only 
one active thyroid gland because chronic TSH suppression leads to atrophy of the contralateral 
gland.  In contrast, both thyroid glands are detected in cats with bilateral disease, despite the lack 
of circulating TSH.  Bilateral hyperthyroidism typically results in asymmetric thyroid 
enlargement.  The literature has reported that 3%-20% of hyperthyroid cats have abnormal 
functional thyroid tissue located in the cranial mediastinum, which can only be detected with 
scintigraphy.50  Histopathology remains the gold standard for the diagnosis of thyroid carcinoma, 
however, thyroid scintigraphy can aid in the presumptive diagnosis via detection of masses that 
cannot be palpated.  Although one report found no reliable features on scintigraphy to distinguish 
thyroid carcinoma from adenoma,51 others have described associations between malignancy and 
certain radionuclide uptake patterns: uptake in the cranial mediastinum; detection of multiple and 
extensive regions of uptake; distorted, irregular uptake with activity extending beyond the 
thyroid gland margins; and detection of linear multifocal uptake patterns.52,53,54 
 
 Thyroid Ultrasound 
Ultrasonography can be utilized to evaluate the architecture of the thyroid glands, 
however, it is not useful for the diagnosis of hyperthyroidism.  The normal feline thyroid gland is 
thin, fusiform-shaped, approximately 15-25mm in length, with uniform echogenicity, surrounded 
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by a thin, hyperechoic capsule.55  Thyroid ultrasound examination of 15 hyperthyroid cats 
revealed thyroid glands that were larger with rounded margins, mixed echotexture, and increased 
vascularity compared to the appearance of the same glands 6 months after successful 131I 
therapy.56  Sonographically determined volumes of single adenomatous glands from 
hyperthyroid cats ranged from 552-572mm3 compared with thyroid volumes ranging from 40-
140mm3 determined using cats with normal thyroid function.56,57 
 
 Treatment Options for Feline Hyperthyroidism 
The major modalities currently available for the treatment of cats with hyperthyroidism 
include non-curative therapy via medical management with methimazole (Tapazole) and dietary 
management with Hill’s® Prescription Diet® y/d® Feline, or curative therapy with surgery 
(thyroidectomy) and/or radioactive therapy (131I).  Each treatment modality has advantages and 
disadvantages and the treatment decisions should be based on the needs of each individual cat 
and owner.   
 
 Methimazole 
Medical management with oral methimazole is a commonly used non-curative treatment 
modality in the United States.  Oral methimazole therapy provides an opportunity to adjust 
dosage of anti-thyroid medication over time as needed, however non-curative treatment 
necessitates daily life-long administration of medication to control hyperthyroidism.  
Methimazole is a thiourylene compound that blocks the synthesis of thyroid hormones by 
inhibiting thyroid peroxidase activity, leading to reduced organification of iodide, as well as 
inhibition of the coupling of iodothyronines to form T3 and T4.58  Methimazole does not inhibit 
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the release of preformed, stored thyroid hormone, which delays the normalization of T4 
concentrations by 2-4 weeks after initiating therapy.36  Methimazole has a serum half-life of 2.3 
hours in hyperthyroid cats and 4.7 hours in normal cats.58,59  Carbimazole, another antithyroid 
medication is metabolized to methimazole after oral administration making it equally effective as 
methimazole.  Carbimazole is widely used in Europe and Asia for treatment of feline 
hyperthyroidism but is not licensed for use in the United States.29   
Evaluation of 262 hyperthyroid cats treated with methimazole as the sole therapy, 
revealed a decrease in TT4 concentration after 2-3 weeks of therapy.36  Side effects associated 
with oral methimazole were reported in approximately 18% of treated cats and included 
vomiting, anorexia, depression, and self-induced excoriations of the face or neck, blood 
dyscrasias and hepatopathy.36  These effects are typically observed within 2-4 weeks of initiation 
of methimazole therapy.  If less severe side effects such as vomiting are observed, a decrease in 
methimazole dose can be attempted, however if the more serious blood dyscrasias or 
hepatopathy occur, the use of methimazole should be discontinued immediately, and supportive 
care should be instituted as necessary. 
  The recommended starting dose is 2.5mg methimazole per os twice daily.60  Although 
once daily dosing has been advocated, twice daily dosing has been found to be more effective.61  
After 2-3 weeks on the starting dose, the serum TT4 should be determined; the target TT4 
concentration is in the lower half of the reference interval.60,61  A recent study determined that 
the timing of blood collection after methimazole administration is not crucial and does not affect 
the ability to assess the therapeutic response.62  Continued monitoring of TT4 concentrations 
should occur every 2-3 weeks after a dosage change, 3 months after initial stabilization of TT4, 
and then every 6 months.60  If the recheck serum TT4 concentration is within, or just above, the 
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reference interval, the dose should be maintained.  If the serum TT4 concentration is below the 
reference interval, a dose reduction of 2.5 mg per day is indicated.60  If serum TT4 remains 
significantly elevated despite therapy, compliance should first be assessed and if judged 
adequate, the methimazole dose should be increased by 2.5mg per day.60  Although the effects of 
methimazole on TT4 values are typically observed within the first week of therapy initiation, 
resolution of clinical signs may not be observed for up to 6 weeks after euthyroidism is restored. 
Hyperthyroid cats with concurrent chronic kidney disease (CKD) can present a treatment 
dilemma.  Multiple studies have confirmed that treatment of hyperthyroidism with methimazole 
(as well as 131I and thyroidectomy) decreases glomerular filtration rate (GFR).63,64,65  Although 
the decrease in GFR is a result of return to a euthyroid state rather than a consequence of the 
particular anti-thyroid therapy used, the decreased renal excretion can either unmask previously 
undiagnosed CKD, or exacerbate known CKD.  In non-azotemic cats with unrecognized early 
CKD, it remains difficult to predict the magnitude of the GFR decrease or the development of 
azotemia following successful treatment of hyperthyroidism.  For this reason, it is historically 
recommended that treatment of cats with previously diagnosed renal disease start at a lower dose 
of methimazole, such as 1.25mg twice daily or 2.5mg once daily.  In addition, a trial with oral 
methimazole is often recommended prior to pursuit of either thyroidectomy or 131I to assess 
possible adverse renal function effects after restoration of euthyroidism.   
During oral methimazole therapy, most cats exhibit only mild changes in renal function 
(<30% increase in serum creatinine), which stabilizes within approximately one month after 
successful treatment of hyperthyroidism.64,65  In addition, although it is not uncommon for cats to 
experience azotemia after successful treatment of hyperthyroidism, it has been shown that those 
cats that develop azotemia post-methimazole or I131 therapy do not have a decreased overall 
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survival time compared with hyperthyroid-treated cats that remain nonazotemic.66  There is 
increasing evidence that maintenance of a hyperthyroid state is detrimental to long-term renal 
function.  For example, when evaluating the N-acetyl-β-D-glucosaminidase index (NAGi), a 
specific marker of active proximal tubular damage, in 24 nonazotemic hyperthyroid cats treated 
with methimazole, the high levels of NAGi in hyperthyroid cats decreased following therapy, 
indicating the renal changes associated with hyperthyroidism can be reversed.67  Therefore, 
despite the risk for reduced renal function, maintaining TT4 concentration in the lower half of the 
reference interval is indicated for affected cats unless there is a profound increase in azotemia 
that adversely affects the cat’s quality of life. 
Although post-therapy azotemia has not been associated with decreased survival times, 
cats with hyperthyroidism and evidence of preexisting CKD treated with oral methimazole or 131I 
had significantly shorter survival times than hyperthyroid cats that did not have evidence of renal 
disease.68  Overall, the median survival time of cats treated with methimazole alone has been 
reported as approximately 2 years, while those treated with methimazole followed by 131I had a 
median survival time of 5.3 years.68  Another study of 300 hyperthyroid cats treated with oral 
methimazole or carbimazole alone or in combination with thyroidectomy found the overall 
median survival time to be 417 days.20  Of these 300 cats, the azotemic hyperthyroid cats had a 
significantly shorter median survival time (178 days) than non-azotemic cats (612 days).20 
In addition to oral methimazole, compounded topical preparations of methimazole are 
available that are absorbed transdermally.  Initial studies reported the bioavailability of 
transdermal methimazole to be poor after application of a single dose applied to the pinnae of  
healthy cats.69  However, long-term use of topical methimazole decreased TT4 concentrations 
and resulted in a restored euthyroidism.69  Although the overall efficacy of transdermal 
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methimazole was less than oral methimazole, and oral methimazole was significantly more 
effective than the transdermal formulation at two weeks post-therapy, by four weeks post-
therapy the initial difference in TT4 concentrations was no longer significant.71  This data 
suggests that chronic use of transdermal methimazole can be effective in lowering TT4 
concentrations.71  The recommended initial dose of the transdermal formulation is 5-10mg per 
cat, and once daily application appears to be as effective in controlling TT4 as twice-daily 
application.72,73  Gastrointestinal side effects were found to occur less frequently with the 
transdermal formulation compared with the oral formulation.71  Additional adverse effects 
associated with the transdermal formulation include mild crusting and erythema at the site of 
application.  Overall, transdermal methimazole may be a viable option for some patients, but it 
must be remembered that whenever using compounded medications, that different compounded 
products can vary in efficacy and safety. 
 
 Hill’s® Prescription Diet® y/d® Feline 
The use of a controlled-iodine diet is a newly developed therapy for feline 
hyperthyroidism.  The only commercial iodine-controlled diet available for the management of 
feline hyperthyroidism is Hill’s® Prescription Diet® y/d® Feline.  Iodine is the major mineral 
component of thyroid hormones and its only known biologic function is in the synthesis of T3 
and T4 hormones.34  Iodine content in commercial cat foods varies widely, ranging from 
undetectable, to greater than 35 parts per million (ppm).  Absolute dietary iodine requirements 
for cats are unknown, and the precise requirements are difficult to determine since the thyroid 
gland is able to adapt to wide variations in iodine intake.34  In addition, other dietary ingredients 
such as perchlorate can interfere with thyroid usage of iodine and iodine measurements by 
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analytical methods.34  y/d® Feline has a reduced iodine content, allowing decreased thyroid 
hormone production, and requires strict dietary compliance for successful management of 
hyperthyroidism.  Concurrent use of this diet and methimazole is not recommended. 
The effects of dietary iodine restriction on the thyroid gland were evaluated by feeding 9 
cats with naturally occurring hyperthyroidism diets containing either 0.47 ppm, 0.28 ppm, or 
0.17 ppm iodine on a dry matter basis.74  When fed either the 0.47 ppm iodine or 0.28 ppm 
iodine diet, 8 out of the 9 cats became euthyroid, while all 9 cats became euthyroid when fed the 
0.17ppm iodine diet.74  Subsequent studies showed that hyperthyroid cats fed diets with ≥ 0.39 
ppm iodine did not maintain TT4 concentrations within the reference interval, while cats fed diets 
with ≤ 0.32ppm iodine resulted in euthyroidism in 90% of hyperthyroid cats.75,76 
In a study of client-owned hyperthyroid cats, feeding a controlled iodine diet (0.32ppm 
on a dry matter basis) decreased TT4 concentration and improved clinical signs after consuming 
the diet for 4 weeks.77  This study also found that 37% of the cats remained hyperthyroid 4 
weeks posttreatment, and when reevaluated at 8 weeks posttreatment, 25% of cats remained 
hyperthyroid.77  There were no adverse effects associated with feeding the iodine-controlled 
diet.77  Although controlling dietary iodine appear to be safe, and result in a significant decline in 
TT4, there is concern that some cats remain hyperthyroid, and many cats do not achieve TT4 
concentrations in the lower half of the reference interval, indicating optimal control of 
hyperthyroidism may be difficult via diet modification alone.   
 
 Thyroidectomy 
Thyroidectomy is a curative treatment option for feline hyperthyroidism, but the 
popularity of surgical treatment has declined over the past decade, in part due to the risk of 
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significant post-operative complications and because of the development and availability of non-
surgical treatment options.  Since over 70% of hyperthyroid cats have bilateral thyroid disease,2 
curative surgery requires bilateral thyroidectomy for most cats.78  Multiple different surgical 
procedures have been described elsewhere.78,79,80,81  Morbidity associated with surgical 
approaches results from disruption of important structures in proximity to the thyroid glands 
including the parathyroid glands, the carotid arteries, jugular veins, and recurrent laryngeal 
nerves.  The most serious post-operative complication is severe hypocalcemia caused by 
iatrogenic damage to, or removal of, the parathyroid gland(s) during surgery.78,79,80  Horner’s 
syndrome, and laryngeal dysfunction, and/or laryngeal paralysis are other potential surgical 
complications.78,79,80  Along with surgical complications specific to the thyroidectomy, geriatric 
hyperthyroid cats are often in poor body condition and may have concurrent disease(s), making 
them less desirable anesthetic candidates.  In addition to surgical complications, treatment 
failures can also occur leading to persistent hyperthyroidism or permanent hypothyroidism.  
Persistent hyperthyroidism can result from incomplete thyroidectomy, or presence of 
unsuspected ectopic thyroid tissue, while cats that receive a complete bilateral thyroidectomy are 
at risk for permanent hypothyroidism.78,79,80 
When evaluating the survival times of 101 cats that underwent either unilateral or 
bilateral thyroidectomy, 2 cats died within 72 hours of surgery.3  Post surgical follow-up 59 
months post-thyroidectomy revealed 57 cats were still alive with a median survival time of 1.9 
years and 44 cats that were no longer alive and had a median survival time of 1.1 years.3  
Reported causes of death included renal failure, other malignant tumors, megacolon, aortic 
thrombosis, respiratory problems, seizures, urinary tract problems, viral infections, and liver 
disease.  Ultimately, if thyroidectomy is chosen as the primary treatment for hyperthyroidism, 
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euthyroidism should be achieved prior to surgery via medical or dietary management.  
Euthyroidism at the time of surgery may diminish the risk for cardiac complications associated 
with anesthesia and permits assessment of renal function prior to thyroidectomy.  
 
 Radioiodine Therapy 
Radioiodine (131I) is another curative treatment for feline hyperthyroidism, and is the 
treatment of choice for most cats due to its high cure rate and minimal side effects.  Because 
iodine transporters on thyroid cells do not differentiate 131I from naturally occurring iodine, the 
radioactive isotope is able to concentrate within the thyroid gland.  131I emits β-particles and γ-
rays, which destroy any surrounding functional thyroid tissue.55  β-particles cause the majority of 
the clinical effect by causing pyknosis and necrosis of thyroid follicular cells as well as vascular 
and stromal fibrosis of the gland.55  The emitted radiation travels on average only 400µm within 
thyroid tissue and spares surrounding tissues such as the parathyroid glands.55  In addition, 
atrophied thyroid tissue is unaffected by131I due to its inability to uptake iodine, making 131I the 
only treatment modality to specifically target hyperfunctioning thyroid tissue.82 
131I is typically administered by subcutaneous injection, although intravenous and oral 
administration is also acceptable.37  Several methods for  calculating an 131I dose have been 
described.53,55,83,84  Ultimately, treatment protocols that use variable 131I doses (tailored to 
individual cats) have no advantage over protocols that employ a fixed 131I dose, thus, most 
treatment centers report use of a fixed dose protocol that administers 3-6mCi per cat.37,50,82,83  A 
study that evaluated 524 hyperthyroid cats treated with radioiodine used a single dose of 2-6mCi 
131I.37  The administered dose was determined using a combination of severity of clinical signs, 
magnitude of serum T4 elevation and size of the thyroid gland(s) measured via digital palpation.37  
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The investigators reported that there was complete resolution of clinical signs of hyperthyroidism 
and return of serum total T4 concentration to within the reference interval in 94.2% of cases 
within 6-12 months of radioiodine therapy; only 8 cats remained hyperthyroid and 11 developed 
clinical hypothyroidism 12 months after 131I treatment.37  Based on these results, it is 
recommended that cats that remain hyperthyroid after an initial 131I treatment should not undergo 
a second treatment until persistent hyperthyroidism has been documented at least 6 months post 
therapy.37   
131I doses of 10-30 mCi carries the best chance of completely destroying malignant 
thyroid tissue, making it the treatment of choice in cats with confirmed thyroid carcinoma, 
regardless of tumor location, including pulmonary metastases.53,85  Larger doses of 131I are 
needed for carcinomas because malignant thyroid cells do not concentrate or retain 131I as 
effectively as adenomatous cells.51,53,85  The use of high dose radioiodine in cats after 
thyroidectomy for carcinoma has been associated with a high rate of post-treatment 
hypothyroidism, requiring thyroxine supplementation.85  However, another study that evaluated a 
single high-dose of 131I as the sole therapy, found that 6 out of 7 cats with confirmed thyroid 
carcinoma had complete clinical resolution of hyperthyroidism and none of the cats had 
clinically significant hypothyroidism requiring supplementation post-131I treatment.51  
Potential disadvantages to 131I therapy include persistent hyperthyroidism requiring a 
second 131I treatment or use of anti-thyroid medication, as well as post-131I hypothyroidism.37,82  
Of 524 cats treated with a mean radioiodine dose of 3.4 mCi, the percentage of cats with relapse 
of hyperthyroidism was only 2.5% and the prevalence of clinical hypothyroidism requiring 
thyroid supplementation was only 2.1%.37  Additional disadvantages of radioiodine therapy 
include the need for patients to be housed separately for 7-10 days after treatment or until 
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radioactivity falls to safe levels as determined by state regulations.  After discharge from the 
hospital, many cats will continue to emit low doses of radiation for approximately 2 weeks, 
which necessitates additional precautions be implemented to avoid unnecessary exposure of pet 
owners.  In addition to specific in-hospital housing requirements, staff with radiation safety 
training are needed to care for the cats in the post-treatment period.  Due to these factors, there is 
a relatively high upfront (but one time) cost for 131I therapy.  
In general, 131I  is a highly efficacious treatment modality, with 95% of cats becoming 
euthyroid within 3 months of receiving a single treatment.55  The median survival times 
associated with 131I therapy have been found comparable to or longer than those reported for cats 
that undergo surgical thyroidectomy.3  The median survival time of the above-mentioned 524 
cats that received 131I was approximately 2 years.37  Other reported median survival times of cats 
that received 131I for treatment of treatment of hyperthyroidism are 25 months,86 and four years.68  
Overall due to the low rate of short and long-term effects of radioiodine therapy, as well as 
comparable to increased survival times as compared to thyroidectomy, 131I remains the curative 
treatment of choice for feline hyperthyroidism.  
 
 Conclusions 
 Hyperthyroidism is the most commonly diagnosed endocrinopathy in older cats, and its 
recognition and diagnosis are important to small animal practitioners.  The pro’s and con’s of the 
available treatment options as well as long-term monitoring requirements should be discussed in 
detail with cat owners to ensure the most appropriate treatment plan is initiated for each 
individual cat.  The costs associated with each treatment option vary based on the facility, and 
the relatively larger upfront cost of thyroidectomy and 131I must be compared to the monthly 
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costs associated with the non-curative, lifelong treatment options.  Due to the lack of a 
randomized trial evaluating all the different treatment options, it is difficult to state the 
superiority of one treatment modality over the other, emphasizing the need to tailor therapy to 
each individual cat and owner needs. 
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Chapter 2 - A Review of the Renal Effects of Feline 
Hyperthyroidism 
 Introduction to Feline Chronic Kidney Disease 
Hyperthyroidism and chronic kidney disease (CKD) are both common diseases in the 
geriatric feline population and the frequency of concurrent hyperthyroidism and CKD in cats 
increases with age.68,87  CKD is estimated to affect 1-3% of all cats,88 and over 30% of cats older 
than 15 years of age.89  Nephron damage associated with CKD is usually considered irreversible, 
and is often progressive.  Most feline CKD is associated with tubulointerstitial lesions, although 
a primary etiology is often not determined.  Renal diseases that have been linked with the 
development of CKD include glomerulopathies, pyelonephritis, nephrolithiasis, polycystic 
kidney disease, amyloidosis, and neoplasia.  In some cases, the initial underlying renal insult 
remains undetected or untreated which allows continued damage to nephrons.  It is also possible 
that when the initial insult is not resolved, progressive kidney damage becomes “self-
perpetuating”.  CKD can progress over a period of months or years and is a leading cause of 
death in cats.  To better classify CKD, the International Renal Interest Society (IRIS) has 
recommended a staging system that utilizes serum creatinine (SCr) concentration, proteinuria, 
and systolic blood pressure to help guide appropriate therapy as well as prognosis.88  The median 
survival time of cats with CKD varies according to the IRIS stage of disease, with more 
advanced stages having decreased survival.  A subset of CKD cats within the IRIS Stage 2 group 
(SCr concentrations between 2.3 mg/dl [203 µmol/l] and 2.8 mg/dl [250 µmol/l]) had a median 
survival time of 1,151 days, while cats with IRIS CKD Stages 3  (SCr concentrations between 
2.9 mg/dl [251 µmol/l] and 5.0 mg/dl [440 µmol/l]) or stage 4 (SCr concentrations >5.0 mg/dl 
[>440 µmol/l]) had a median survival time of 679 and 35 days, respectively.90  It is usually not 
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possible to improve renal function in CKD, as irreversibly damaged nephrons are replaced by 
fibrous scar tissue, and therefore treatment is lifelong and aimed at stabilizing renal function. The 
reported median survival time for cats with hyperthyroidism ranges from 1.6 years to up to 4 
years,20,37,68,86 while cats classified as having CKD prior to treatment of hyperthyroidism have 
shorter survival times of 0.5 years to up to 2 years.20,68 
 Effects Of Thyrotoxicosis On The Kidney 
Thyrotoxicosis leads to hemodynamic changes throughout the body, many of which 
specifically affect the kidneys.  One example is increased activation of the renin-angiotensin-
aldosterone system (RAAS) which has been shown in both people and cats with naturally 
occurring hyperthyroidism.91,92  Increased RAAS activation is not only due to T3 having a direct 
effect on renin gene expression, but also T3 mediated relaxation of vascular smooth muscle cells 
causing decreased peripheral vascular resistance by as much as 50%.91,93,94,95  Secondary to the 
decrease in systemic vascular resistance, the effective arterial filling volume decreases and the 
RAAS is upregulated in an effort to restore effective arterial filling volume via increased renal 
sodium reabsorption within the proximal tubule and loop of Henle.91,93  In addition, 
hyperthyroidism is associated with increased responsiveness and upregulation of β-adrenergic 
receptors within cardiac tissue as well as the renal cortex,96 that can lead to increased 
sympathetic nervous system activity and increased RAAS activity.91  Increases in RAAS 
activation leads to an overall increase in angiotensin II which is a potent vasoconstrictor of the 
glomerular efferent arteriole leading to increased glomerular pressure and glomerular 
hyperfiltration. 
The other major effect of hyperthyroidism on the kidneys is an overall increase in 
glomerular filtration rate (GFR).  This occurs secondary to hyperthyroid-associated decreased 
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vascular resistance, combined with increased cardiac output, and overall increased blood volume, 
causing increased renal blood flow (RBF), increased glomerular capillary hydrostatic pressure, 
and increased GFR.  Additionally, GFR upregulation is enhanced secondary to thyroid hormone-
induced increases in expression of mRNAs encoding for chloride channels, leading to increased 
chloride absorption in the proximal tubule and loop of Henle.97  The decreased intratubular 
chloride load is sensed in the distal tubule by the macula densa and via tubuloglomerular 
feedback, GFR is further upregulated.   
Renal proteinuria is a common finding in cats with hyperthyroidism as well as cats with 
CKD.20,30  Increases in proteinuria associated with CKD  have been hypothesized to occur 
secondary to increased glomerular capillary pressure and impaired tubular resorptive capacity of 
remaining nephrons.98,99  Although the mechanism of proteinuria in hyperthyroidism is 
incompletely understood, clinically significant systemic hypertension due to hyperthyroidism is 
less common than initially thought,20,100 thus the transmission of systemic hypertension to the 
glomeruli, may not be an important cause of proteinuria in hyperthyroid cats.  Proteinuria is a 
risk factor for the development of azotemia,101 and the progression of azotemic CKD.102  
Fortunately, the magnitude of proteinuria tends to decrease once the euthyroid state is 
restored.20,103  
The presence or absence of azotemia (assessed via serum creatinine and serum BUN 
concentrations) and measurement of GFR are commonly used to evaluate renal excretory 
function in cats.  The hypermetabolic state that accompanies hyperthyroidism leading to 
increased RBF and increased GFR, however, may affect the ability to interpret these parameters.  
Decreased creatinine production due to a reduction in muscle mass, as well as the 
aforementioned increases in GFR in hyperthyroid cats can make pre-treatment assessment of 
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renal excretory function using only the serum creatinine concentrations difficult, and can ‘mask’ 
existing kidney disease.  In addition, the gold standard for assessment of renal excretory function 
is GFR measurement, however, the hyperthyroid-induced increases in RBF and GFR can make 
renal function appear normal despite the presence of CKD.  These masking effects may result in 
the diagnosis of CKD being made only after euthyroidism is restored.  The overall prevalence of 
concurrent azotemia and hyperthyroidism prior to hyperthyroid therapy in cats has been reported 
to range from 10%-23%,13,20,68 while post-treatment azotemia occurs in approximately 15-49% of 
hyperthyroid cats.20,65,68  
 
 Effects Of Hyperthyroidism Treatment On Kidney Function 
Regardless of the modality utilized, successful treatment of hyperthyroidism decreases 
renal excretory function, resulting in an increase in the serum creatinine concentration and a 
decrease in the GFR.30,63,64,65,86,104,105  For example, in a study of 22 cats treated with 131I, there 
was a significant decrease in GFR observed between day 6 and day 30 post-131I treatment, and 
cats with normal renal excretory function prior to therapy had significant increases in serum 
creatinine and BUN concentrations within 30 days following treatment.104  When evaluating the 
long-term renal effects of 131I in 27 cats, serum creatinine concentration increased significantly at 
1-month post treatment and continued to increase at 3 and 6 months post-131I.65  Conversely, 
GFR decreased significantly at 1 month after treatment, and continued to decrease 6 months after 
treatment, although the decrease beyond 1 month was not significant.65  Similar results were 
observed in another study,30 in which GFR decreased significantly until four weeks post-131I 
treatment and then stabilized.30  Additionally, in 268 non-azotemic hyperthyroid cats treated with 
either antithyroid medication alone, or antithyroid medication in combination with 
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thyroidectomy, 15% became azotemic by 8 months post-treatment.20  Importantly, it has been 
shown that cats that develop post-treatment azotemia do not have decreased survival times 
compared with hyperthyroid-treated cats that remain nonazotemic.106  However, cats with 
azotemia prior to initiation of treatment for hyperthyroidism appear to have decreased survival 
compared with cats that become azotemic following treatment.20-68  Collectively, these studies 
indicate that serum creatinine concentration may continue to increase for 6 months after attaining 
a euthyroid state, while GFR decreases for up to 1 month, and then tends to stabilize.  
 
 Effects Of Hypothyroidism On The Kidney 
Hypothyroidism has been associated with decreased GFR in dogs,107 and similar 
physiology is suspected in cats.  Diminished GFR could have significant consequences for 
hyperthyroid cats with preexisting renal disease that become hypothyroid as a result of treatment.  
In 80 hyperthyroid cats treated either with anti-thyroid medication alone or in combination with 
thyroidectomy, 28 cats were diagnosed with hypothyroidism 6 months post therapy based on 
decreased total T4 concentration and increased TSH concentration.106  Of these 28 hypothyroid 
cats, 16 (57%) developed post-treatment azotemia which not only was higher than the proportion 
of euthyroid cats that developed post-treatment azotemia (30%), but was associated with a 
significantly shorter survival time than the nonazotemic hypothyroid cats.106  Thus, cats with 
iatrogenic hypothyroidism are not only more likely to develop azotemia, but hypothyroid cats 
with azotemia also have decreased survival.106   When decreasing the dose of anti-thyroid 
medication in hyperthyroid cats that became hypothyroid following medical treatment with anti-
thyroid medication, resolution of azotemia occurred in 50% of cats.108  Based on these findings, 
the importance of identifying and treating cats with iatrogenic hypothyroidism becomes 
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apparent.  Hypothyroidism may not occur for as long as 3-6 months after radioiodine 
treatment,106 so monitoring TT4 for at least 6 months post-treatment is necessary.  A low total T4 
concentration alone is not sufficient for diagnosis of iatrogenic hypothyroidism due to the 
potential for euthyroid sick syndrome.109  The combination of reduced total T4 concentration and 
elevated TSH concentration is consistent with iatrogenic hypothyroidism.  In this circumstance, 
thyroxine supplementation or adjustment of antithyroid medication should be considered.109     
 
 Pretreatment Predictors Of Posttreatment Azotemia 
Although the prognosis for cats that develop post-treatment azotemia is similar to 
hyperthyroid-treated cats that remain nonazotemic,106 the ability to predict which cats will 
experience decreased renal function post-hyperthyroidism therapy has been widely sought after.  
To date, pretreatment values for serum creatinine, serum BUN, and USG have not been shown to 
reliably predict development of azotemia after treatment of hyperthyroidism.13,64,65,66,86,87  In one 
large study, plasma concentration of urea and creatinine were positively correlated and plasma 
globulin concentration was negatively correlated with the development of post-treatment 
azotemia,20 however other studies have not confirmed these results.  Pre-treatment measurement 
of GFR has shown promise for predicting post-treatment azotemia in some studies,104 however 
other studies have shown significant overlap in GFR values.30  For these reasons, novel markers 
of tubular damage have been investigated for predicting development of azotemia after treatment 
for hyperthyroidism.  
Many untreated hyperthyroid cats exhibit mild proteinuria, which when evaluated by 
urine protein to urine creatinine ratio (UPC), has been shown to significantly decrease 4 weeks 
after successful treatment of hyperthyroidism.20,30  In contrast to the UPC, one study 
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demonstrated that the urine albumin to creatinine ratio (UAC) did not decrease with successful 
treatment of hyperthyroidism suggesting that albuminuria may not be a major contributor to the 
proteinuria observed in hyperthyroid cats.20  Although resolution of proteinuria (as measured by 
UPC) after treatment of hyperthyroidism is an important finding, the use of pretreatment UPC 
values as a predictor of post-treatment azotemia was not supported.20,30 
N-acetyl-β-D-glucosaminidase (NAG) is a lysosomal glycosidase enzyme found 
primarily in the epithelial cells of the proximal convoluted tubule.  Increased concentration of 
this enzyme in the urine is considered a specific marker of active proximal tubular damage.110  
Urine NAG activity is typically expressed in a ratio with urine creatinine, referred to as NAG 
index (U/g) (NAGi).  In 24 hyperthyroid cats treated with methimazole, the pre-treatment NAGi 
did not differentiate azotemic euthyroid cats from nonazotemic euthyroid cats after treatment.67  
However, the NAGi measured in untreated hyperthyroid cats decreased following therapy, 
indicating the renal tubule changes associated with hyperthyroidism can be reversed following 
return to euthyroidism.67  
Urinary retinol binding protein (uRBP) is a sensitive indicator of renal tubular damage in 
people, with minor tubular dysfunction leading to increased urinary excretion of uRBP.111   
When comparing uRBP levels (expressed as uRBP:urine creatinine ratio) between clinically 
healthy cats, cats with CKD, and cats with hyperthyroidism, the CKD and hyperthyroid groups 
had elevated uRBP, while uRBP in the healthy cats was below the assay sensitivity.112  In 10 cats 
with naturally occurring hyperthyroidism evaluated pre- and post-131I treatment, a significant 
decrease in the uRBP:urine creatinine ratio was detected following successful treatment.113  This 
data suggests that return to a euthyroid state can reverse some of the tubular changes that result 
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in increased uRBP in the hyperthyroid state, however uRBP has not been shown to be predictive 
of post-treatment azotemia.113 
 As previously discussed, there is increased activation of the RAAS in hyperthyroid 
cats.91,92  The subsequent elevations in angiotensin-II, which preferentially constricts the efferent 
glomerular arteriole, may lead to decreased peri-tubular blood flow and peri-tubular hypoxia.  
Vascular endothelial growth factor (VEGF) is a regulator of blood vessel growth, and in people 
is produced by renal proximal tubular cells in response to hypoxia in vitro.114  Inasmuch as 
urinary vascular endothelial growth factor:creatinine ratio (VEGFCR) may be a marker for renal 
tubular hypoxia, its potential association with the development of azotemia in hyperthyroid cats 
following treatment has been investigated.115  VEGF excretion was positively associated with 
both hyperthyroidism and RAAS activation, and VEGF excretion decreased following treatment 
of hyperthyroidism.  However, this study also revealed that VEGFCR was not correlated with the 
development of azotemic chronic kidney disease post-treatment, and thus, tubular hypoxia may 
not be a mechanism for renal damage in hyperthyroid cats.115  
 Conclusions 
To date, no single, readily available, serum or urinary biomarker is able to reliably 
predict post-treatment renal function in hyperthyroid cats.13,20,64,65,66,86,87  Although successful 
treatment of hyperthyroidism has the potential to unmask pre-existing CKD, the associated 
changes in renal function are usually mild, renal function typically stabilizes within 6 months of 
the hyperthyroid treatment, and overall survival of those cats that do become azotemic does not 
differ from non-azotemic cats. Thus, treatment of hyperthyroidism is recommended with the 
target total T4 in the lower half of the reference interval, without creating hypothyroidism.   
When treating non-azotemic hyperthyroid cats, it is important to remember that increases in 
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serum creatinine concentrations may occur over several months, so monitoring renal function for 
6 months following restoration of euthyroidism is recommended. When treating cats with 
evidence of CKD prior to treatment, the decreased survival times associated with pre-therapy 
CKD should be discussed with owners, and continued monitoring of renal function for months 
following return euthyroidism is necessary.  In addition, due to the increased risk of azotemia 
and poor prognosis in cats with iatrogenic hypothyroidism, total T4 (and TSH when appropriate) 
concentrations should be monitored for at least 6 months after euthyroidism is achieved, and 
iatrogenic hypothyroidism should be corrected via adjustment of anti-thyroid medication or 
thyroid supplementation when necessary. 
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Chapter 3 - Assessment of Renal Function in Hyperthyroid Cats 
Managed with a Controlled Iodine Diet. 
 Introduction 
Since its recognition in the late 1970’s,1 hyperthyroidism has become the most commonly 
diagnosed endocrinopathy in older cats.  Treatment modalities have classically included 
antithyroid medication (methimazole or carbimazole), thyroidectomy, and radioiodine (131I) 
therapy.  Previous studies have demonstrated that glomerular filtration rate (GFR) significantly 
declines following treatment of hyperthyroidism independent of the treatment modality 
used.63,64,65,104  Recently, Hill’s® Prescription Diet® y/d® Feline, a controlled iodine food, has 
been introduced as a reversible treatment option for management of feline hyperthyroidism.74,75  
In client-owned hyperthyroid cats, feeding y/d® Feline lead to a significant decline in total T4 
concentrations and resolution of clinical signs of hyperthyroidism within 4 weeks without 
adverse effects.77  In contrast to other treatment modalities, the serum creatinine concentration in 
cats fed the iodine-controlled diet, significantly decreased (p = 0.001) after four weeks of 
therapy.  Additional effects of Hill’s y/d® on renal function in hyperthyroid cats have not been 
evaluated.   
GFR measurement is considered the gold standard for evaluation of renal excretory 
function, however due to increased time, labor and expense, plasma clearance techniques that 
approximate GFR are not routinely performed in clinical practice.  Measurement of serum 
creatinine concentration is the most commonly assessed renal excretory function parameter, 
however, the loss of muscle mass in hyperthyroid cats can decrease production of creatinine and 
decrease its serum concentration.  Serum symmetric dimethyl arginine (SDMA) is a byproduct of 
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protein methylation that is largely excreted by the kidneys.116  In people, serum SDMA is an 
endogenous marker of renal function, has been shown to correlate with GFR, and appears to be a 
more sensitive biomarker than serum creatinine for assessing renal dysfunction.117  Recently the 
reciprocal of serum SDMA was found to be linearly related to GFR in cats with chronic kidney 
disease (CKD).118  In addition, there is evidence that serum SDMA is a sensitive biomarker for 
CKD in cats; allowing earlier detection of CKD compared with serum creatinine 
concentration.119   
The first aim of this study was to evaluate the effects of y/d® Feline on renal function in 
client-owned cats with natural occurring hyperthyroidism after 6 months of treatment.  Renal 
function was assessed by plasma clearance of 99mTc-labeled diethylenetriaminepentaacetic acid 
(99mTc-DTPA), and serum creatinine and SDMA concentrations.  The second aim was to 
evaluate the effects of the controlled-iodine food on overall muscle mass via ultrasonographic 
evaluation of the epaxial muscle diameter (EMD).  It was hypothesized that controlled dietary 
iodine as a treatment for hyperthyroidism would create a euthyroid state without a decrease in 
renal function.  In addition, it was hypothesized that feeding y/d® Feline to hyperthyroid cats 
would not decrease muscle mass. 
 Materials and Methods 
 Animals 
Cats were recruited from the Kansas State University Veterinary Health Center (KSU-
VHC) patient population and from surrounding primary care veterinary hospitals.  The 
Institutional Animal Care and Use Committee of Kansas State University approved the study and 
written owner consent was obtained prior to patient entry into the study. 
  34 
 Inclusion Criteria 
Newly diagnosed, or previously diagnosed hyperthyroid cats on anti-thyroid medication 
were eligible for inclusion in the study.  Any anti-thyroid medication was discontinued for at 
least one week prior to evaluation at KSU-VHC.  Hyperthyroidism was confirmed via elevated 
chemiluminescent enzyme immunoassay (CLEIA) total thyroxine (T4) [TT4] concentrationa, a 
Michigan State University (MSU) thyroid function panel (TT4, TT3, fT4ED, fT3, and TSH)b and 
thyroid technetium scan.   
 Exclusion Criteria 
Cats were excluded from the study if they had previous 131I treatment for 
hyperthyroidism, or evidence of significant comorbidities such as diabetes mellitus, neoplasia, 
and chronic kidney disease.  In addition, if the patient had a fractious temperament that did not 
allow frequent handling or multiple sample collections, they were excluded.  Finally cats were 
excluded if they refused to reliably eat the diet, or if the owners were unable to ensure that y/d® 
Feline was the only source of nutrition throughout the study period. 
 Study Design 
A 6-month, prospective, observational study was conducted.  Cats that fulfilled the 
inclusion criteria were transitioned to Hill’s y/d® Feline either dry or canned formulations, based 
on cat/owner preference, as the sole source of nutrition over the course of one week.   Owners 
were provided instructions detailing diet transition guidelines with the goal of meeting the cats 
resting energy requirements (RER) with y/d® Feline by the end of the one week period.  RER 
was calculated for each cat using the equation of 1.4[(30 x body weight (kg) + 70] and the 
amount of dry and/or canned food required to meet these requirements was discussed with the 
owners.  In addition, food storage information was provided to help ensure no cross-
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contamination with other foods or products that could potentially contain iodine.  Each cat was 
re-evaluated after consuming the controlled-iodine diet exclusively for 1 month, 2 months, 3 
months and 6 months.  The cats’ willingness to eat the food, and owners’ ability to maintain 
strict dietary compliance was discussed at each visit. 
 Initial Hospital Visit 
Initial evaluation to confirm the diagnosis of hyperthyroidism and to rule out 
comorbidities included physical examination, body weight, CLEIA TT4 concentrationa, MSU 
thyroid function panelb, complete blood count (CBC), serum biochemistry, serum SDMAc, 
urinalysis, aerobic bacterial urine culture, urine protein to creatinine ratio (UPC), urine gamma-
glutamyl transpeptidase (GGT) to creatinine ratio (UGGTC), semi-quantitative feline specific 
albuminuria assay (ERD)d, Dopplere-measured systolic blood pressure (SBP), thyroid technetium 
scan, plasma clearance of 99mTc-DTPA, and ultrasound assessment of EMD and thyroid gland 
volume. 
 Subsequent Hospital Visits 
A follow-up evaluation was scheduled when the cat had been exclusively eating y/d® 
Feline for 1 month, 2 months, 3 months and 6 months.  Evaluation at 1 and 3 months included 
physical examination, body weight, CLEIA TT4 concentrationa, CBC, serum biochemistry, 
serum SDMAc, urinalysis, UPC, UGGTC, ERDd, and SBPe.  The 2-month evaluation included 
only CLEIA TT4 concentration to help document continued dietary compliance, and the final 6-
month evaluation included all diagnostics performed at 1 and 3 months in addition to repeating 
the MSU thyroid panel, 99mTc-DTPA plasma clearance and ultrasonographic assessment of EMD 
and thyroid gland volume.  All ultrasonographic assessments of the epaxial muscles and thyroid 
glands and were performed by the same board certified radiologist. 
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 Blood and Urine Sample Collection and Analysis 
Blood samples were collected from the jugular or medial saphenous vein.  All urine 
samples were collected by cystocentesis.  Serum was stored at -80°C from each recheck 
evaluation and SDMA concentrations measured as previously described.119  Urinalysis was 
performed using a refractometer for USG, commercially available reagent stripsf for chemical 
evaluation, and standard microscopic sediment examination.  Approximately 2 mL of urine were 
set aside for the ERD, which was performed within an hour of collection and interpreted as either 
negative, low positive, medium positive or high positive.  For statistical analysis, the results of 
the ERD were scored as follows; negative = 0, low positive = 1, medium positive = 2, high 
positive = 3.   Approximately 0.5 mL of urine was saved from each urine sample and refrigerated 
until submitted, within 2 hours, for aerobic culture and sensitivity (initial evaluation and as 
indicated by urine sediment evaluation on subsequent evaluations).  Urine protein was quantified 
using the benzethonium reaction method and urine creatinine was quantified using the buffered 
Jaffe reaction, both with an automated chemistry analyzerg.  The UPC was calculated from this 
data for each urine sample.  Urine GGT was quantified using the enzymatic colorimetric assay, 
and the UGGTC was then calculated using the same urine creatinine value for the UPC 
calculation. 
 Blood Pressure Measurement 
Systolic blood pressure measurements were obtained by use of an ultrasonic Dopplere 
monitor after the cats were acclimated to the hospital environment.  Cats were placed in lateral 
recumbency.  The up forelimb was used for pressure measurement with a neonatal #2 or #3 cuff 
(width approximately 35-40% the circumference of the leg) placed below the elbow.  After 
clipping directly over the common digital branch of the radial artery, 3-4 readings were obtained 
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and the mean was recorded.   Cats that had persistent hypertension (systolic blood pressure 
>180mmHg on ≥ 2 measurements at least 1 week apart) were started on once daily oral 
amlodipineh at 0.625mg per cat, with the dosage adjusted as needed upon reevaluation. 
 Imaging 
The same board-certified veterinary radiologist performed all ultrasonographic 
evaluations of the left and right epaxial muscles and thyroid glands.  When required, ketamine 
(5mg/kg, IV) and diazepam (0.5mg/kg, IV) were administered for sedation.  For the EMD, three 
measurements were taken and the mean recorded.  For the thyroid gland, three measurements of 
each of the following; gland length, width and height, were taken and the mean recorded, the 
volume was then calculated by multiplying the mean length, width and height to give a measure 
of mm3.  Thyroid scintigraphy was performed as previous described.47  The thyroid to zygomatic 
salivary gland ratio was calculated for both thyroid glands, and a ratio > 1.2:1 was considered 
consistent with hyperthyroidism.48  Unilateral disease was defined as one thyroid gland with a 
thyroid to salivary gland ratio >1.2:1 and bilateral disease was defined as both thyroid glands 
with a thyroid to salivary gland ratio >1.2:1. 
 Determination of GFR 
Glomerular filtration rate was determined by analysis of a 99mTc-DTPA plasma 
disappearance curve.  Baseline plasma clearance studies were performed on the second day of 
initial evaluation, after results of screening blood and urine tests had been obtained.  Doses of 
99mTc-DTPA for injection and for a standard were drawn and measured in milicuries (mCi) by 
use of a dose calibrator.   The standard was prepared by placing approximately 1 mCi of 99mTc-
DTPA in a volumetric flask and adding water to make a total volume of 1 L.  Approximately 1 
mCi of 99mTc-DTPA was administered via the cephalic vein.  Pre- and post injection syringe 
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activity was counted, using a scintillation probe, to determine the exact dose of radioisotope 
administered.  Time zero was recorded.  Blood samples were collected via jugular vein, or the 
medial saphenous vessel opposite the injection site at 15, and 120 minutes.  Plasma was 
harvested from centrifuged blood anticoagulated with ethylenediaminetetraacetic acid (EDTA).  
One-milliliter aliquots of the diluted standard and plasma samples were prepared for each sample 
collection time.  A single-channel analyzer system attached to sodium iodide well crystal was 
used to determine radioactivity in each sample.  The GFR was calculated from 99mTc-DTPA 
plasma disappearance curves as previously described.120 
 Statistical Analysis 
Analyses were performed using commercial softwarei.  Descriptive statistics were 
presented as mean ± standard deviation (SD).  Serum creatinine concentration, GFR, and serum 
SDMA were compared using repeated measures ANOVA to analyze the difference between pre 
and post treatment effects.  T-tests were used for evaluation of change over time.  Significance 
was set at p ≤ 0.05. 
 Results 
A total of 18 cats were evaluated as possible participants in the study, of which 15 met all 
of the inclusion criteria.  Of the three cats excluded, one cat was excluded due to refusal to eat 
the food, and another after the owner was unable to ensure strict dietary compliance.  The third 
cat was removed from the study two weeks after the 2-month recheck due to a decreasing 
appetite, despite tempting with food other than y/d® Feline, and worsening lethargy.  Upon 
evaluation, the cat was clinically icteric, with moderate liver enzyme elevations and a diffusely 
hyperechoic liver with rounded margins on abdominal ultrasound.  The cat was admitted to the 
hospital and treatment of presumptive hepatic lipidosis was instituted with IV fluid therapy, 
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vitamin K administration SQ, SAMe, and ursodiol.  An esophageal feeding tube was placed on 
day two and tube feedings were increased to total RER over 3 days.  Unfortunately, the cat had 
minimal response after 6 days of therapy, and the owner requested euthanasia.  Necropsy 
evaluation revealed diffuse, moderate to severe hepatic lipidosis, diffuse, severe pancreatic 
amyloidosis with interstitial fibrosis, and unilateral thyroid adenoma. 
The age of cats included in the study ranged from 7-16 years old with a median of 12 
years of age.  Of the fifteen cats, 13 were spayed females and 2 were castrated males.  Majority 
of cats were domestic short hairs (n=13), and there was one each of the following; domestic long 
hair, Maine Coon cat, and Siamese cross.  All cats had an initial TT4 concentration >56 nmol/L 
(reference interval 10-45 nmol/L) via CLEIA (Table 3.1) and > 49 nmol/L (reference interval 10-
55 nmol/L) via MSU.  Results of the technetium thyroid scan (Table 3.2) revealed all cats had at 
least one thyroid to zygomatic salivary gland ratio of >1.2, consistent with hyperthyroidism.  
Two of the cats had unilateral disease, while 13 had bilateral disease, and no cats had ectopic 
thyroid tissue. 
The mean body weight (kg), USG, UGGTC, ERD, SBP, EMD (left and right [cm]) and 
thyroid gland volume (mm3) at each available evaluation are listed in Table 3.3.  There was no 
difference found between any of these parameters throughout the study period.  Based on 
persistent hypertension on repeat blood pressure measurements, cats 1, 3, 4 and 15 were treated 
with amlodipine (average dose of 0.66 mg by mouth once daily).  Results of the MSU thyroid 
panel for each of the 15 cats pre and posttreatment are listed in Table 3.4, and the mean values 
for CLEIA TT4, GFR, SCr, SDMA and UPC pre and posttreatment are listed in Table 3.5.   
The mean serum CLEIA TT4 concentration significantly decreased (p < 0.001) from a 
pretreatment value of 185.54 ± 138.0 nmol/L to a 6-month posttreatment value of 60.5 ± 35.5 
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nmol/L (reference interval 10-45 nmol/L) (Table 3.5).  These values were similar to the mean 
MSU thyroid panel results of 106.9 nmol/L for the pretreatment value and 57 nmol/L 6-months 
posttreatment.  There was no significant difference in TT4 (CLEIA or MSU) between baseline 
and 6-months posttreatment.  Of the 15 cats that completed the study, 5 cats were euthyroid 
(CLEIA TT4 concentration within reference interval) at the end of the 6-month study period, 
while the remaining 10 cats had TT4 concentrations above the reference interval (Table 3.1).  
Based on the MSU thyroid panel results, 6/15 cats were euthyroid and 10/15 had a TT4 ≤ 60 
nmol/L (Table 3.4).   
There was a significant decrease in serum creatinine concentration between the initial 
evaluation and 6 months posttreatment (p < 0.001).  No significant differences were observed 
between the initial and 6-month posttreatment GFR (p = 0.71), serum SDMA (p = 0.41), UPC (p 
= 0.74, or EMD (p = 0.95 and p = 0.45 for right and left EMD respectively) (Table 3.5). 
 Discussion 
Similar to previous studies assessing the effects of y/d® Feline, the results of this study 
indicate that feeding y/d® Feline to hyperthyroid cats results in a significant decrease in 
circulating TT4 concentration.  Despite the significant decrease in TT4, the circulating TT4 
concentration was still elevated above reference interval in 10/15 (66%) and 9/15 (60%) 
depending on the TT4 assay, of the cats at the end of the 6-month study period.  A potential cause 
for continued hyperthyroidism in these cats could be attributed to either poor patient or owner 
dietary compliance.  Poor dietary compliance was documented in 24/68 cats fed y/d® Feline in a 
previous study,77 however in the present study, no specific concerns about compliance were 
reported by owners at recheck evaluations.  Because many households are not only multi-cat 
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house holds, but also inhabited by other pets, as well as children and intermittent visitors, 
accidental or unknown exposure to other dietary sources is difficult to completely rule-out. 
In contrast to previous studies,30,63,64,65 management of hyperthyroidism with y/d® Feline 
did not result in a decrease in GFR.  The most likely explanation for the lack of significant 
decline in GFR in the present study was the relatively high TT4 concentrations posttreatment.  
Previous studies assessing the effects of treatment on GFR, found TT4 concentrations were 
within or below the reference interval in all cats at the end of the study period.63,64,65,104  Since 
the mean 6-month posttreatment TT4 for cats in the present study was greater than the reference 
interval, post-treatment GFR values for those cats that were euthyroid via CLEIA at 6-months (n 
= 5) were looked as separately from the cats that remained hyperthyroid (n = 10), and no change 
in GFR was observed in the euthyroid group (p = 0.35).  In addition, when evaluating the change 
in TT4 and GFR in previous studies,63,64,65 there was a correlation (r2 = 0.53, p < 0.0001) between 
the TT4 and GFR in each of the studies, whereas no correlation between TT4 and GFR was 
observed in the present study (r2 = 0.06, p = 0.39).   
The lack of decline in GFR could also be associated with the absence of TT4 
concentrations below the reference interval at any time point for any cat in this study.  In 
previous studies,30,63,64,65 the number of cats with TT4 below the reference interval ranged 
between 25-79%.  Without concurrent TSH concentrations, it is unknown whether these cats 
were hypothyroid or euthyroid sick.  It has been previously shown that GFR is negatively 
affected by hypothyroidism in dogs,107 and similar physiology is suspected in cats.  Therefore, 
the potential contribution of hypothyroidism to the decline in GFR with other treatment 
modalities is unknown, however none of the cats in the present study had TT4 concentrations 
below reference interval.   
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Another explanation for the lack of significant decline in GFR in the present study could 
be related to a more gradual decline in TT4 when y/d® diet is used to manage hyperthyroidism 
compared with other treatment modalities.  As already discussed, although there was a 
significant decline in TT4 after 1-month of feeding y/d® Feline, 60-66% of our patient population 
remained hyperthyroid at the end of the 6-month period, with 9/15 (60%) remaining 
hyperthyroid via CLEIA at 1- and 2-months posttreatment, and 12/15 (80%) remaining 
hyperthyroid at 3-months posttreatment.  In a previous study evaluation y/d® Feline in client 
owned cats,77 25% of the patients evaluated remained hyperthyroid at 8 weeks.  The number of 
hyperthyroid cats remaining 2-months after institution of y/d® Feline, could simply be due to 
lack of owner or cat compliance, however, it is also possible that the overall decline in TT4 
occurs more gradually than modalities.  In a study population of cats fed y/d® Feline, serum TT4 
concentrations normalized within 4 to 12 weeks of initiating nutritional management and 90% of 
hyperthyroid cats maintained with the limited-iodine food as the sole source of nutrition became 
euthyroid.76  The slope of TT4 decline in client-owned hyperthyroid cats fed y/d® Feline has not 
been evaluated prior to 1-month posttreatment, however it has been shown that 131I causes a 
significantly decrease just one week post therapy,30 with a corresponding significant decrease in 
GFR, and similar timing for significant declines in TT4 would be expected for bilateral 
thyroidectomy.  The lack of change in EMD throughout this study could also be an indirect 
indicator of a more gradual decline in TT4, and thus more gradual change in overall body 
condition.  Other studies30,65 have sighted increasing muscle mass as a source of increased serum 
creatinine concentrations overtime based on improved body condition, which may be associated 
with a more acute reduction in TT4 allowing body condition changes to be appreciated sooner. 
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 Serum creatinine concentration decreased (p < 0.001) between initial evaluation and 6-
months posttreatment.  This is contrary to other treatment modalities,30,63,65 but similar to another 
study evaluating the effects of y/d® Feline in client owned hyperthyroid cats.77  A possible reason 
for the observed decrease in serum creatinine concentration may be the lower content of heat-
processed meat in the y/d® Feline as compared to other commercial cat foods.  Increased 
consumption of heat-processed meats has been shown to increase circulating creatinine 
concentrations in people,122 presumably associated with increased creatinine absorption from the 
gastrointestinal tract.  A decrease in muscle mass was postulated as a potential cause for the 
decrease in serum creatinine concentration in a previous study,77 however the present study 
showed no change in EMD suggesting decreased muscle mass was less likely to be the cause for 
the decreased serum creatinine concentration.   
The EMD of both the left and right epaxial muscles as determined by ultrasonographic 
measurement did not change over time in our study population.  The evaluation of the epaxial 
muscles for the evaluation of overall muscle mass has been utilized when assessing methods for 
evaluating sarcopenia in old dogs.121   In that study the ultrasonographic margins of the epaxial 
muscles were defined medially by the spinous process of T13, ventrally by the 13th rib and 
dorsally and laterally by subcutaneous fat and normalized for variable skeletal size by dividing 
epaxial muscle area by the height of the body of T13.121  Ultrasonographic measurement was 
compared the CT and radiographic measurement of epaxial muscle height.121  Epaxial muscle 
area was significantly lower in healthy old dogs than young dogs when muscle area was 
measured by ultrasonography or CT, especially when the measurements were normalized for 
vertebral body height, while radiographic measurement did not appear to provide sufficient 
precision.121  It seems reasonable that the use of ultrasonographic measurement of the epaxial 
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muscles in cats would provide similar information regarding overall muscle mass, however this 
has not been specifically evaluated. 
 Similar to GFR, SDMA concentrations did not change at any study time point. Previous 
studies of serum SDMA in cats demonstrated a linear correlation between serum SDMA and 
GFR,118 and the present study found a similar correlation.  Indeed, compared to SCr, serum 
SDMA was more highly correlated with GFR (r2 = 0.50 vs. 0.30, p = 0.04).  Thus, serum SDMA 
may be a better marker for GFR than serum creatinine in hyperthyroid cats.  Further study of 
serum SDMA in hyperthyroid cats is warranted. 
 There was no change in UPC, UGGTC or ERD observed throughout the study period.  
The lack of change in UPC is contrary to other reports,20,30 in which there were significant 
decreases in UPC 4 weeks post 131I treatment.  This difference may be due to the low number of 
cats in our study that had significant pretreatment proteinuria, in comparison to the previously 
reported 85% of cats with pretreatment proteinuria.30  Lack of decline in ERD is similar to a 
previous study that found the urine albumin to creatinine ratio (UAC) did not decrease following 
successful treatment of hyperthyroidism.20  The lack of decline in ERD in the present study may 
suggest that albuminuria is not a major contributor to the proteinuria observed in hyperthyroid 
cats as described elsewhere,20 but is more likely associated with our relatively low number of 
proteinuric cats. 
 A limitation of this study was the relatively small number of cats that were 
considered euthyroid at the end of the study period, effectively decreasing the sample size and 
making data interpretation more difficult.  Every effort was taken to ensure that owners were 
adequately storing and administering the food, while ensuring the cats were not receiving any 
other source of nutrition, however 100% compliance was difficult to confirm.  It is likely that 
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unrecognized non-compliance contributed to the high percentage of cats that remained 
hyperthyroid.  Although there was no difference found in the change in GFR vs. change in TT4 
in these five-six euthyroid cats, confirmation of this finding is warranted with a larger sample of 
euthyroid cats prior to and following treatment with y/d® Feline. 
 Conclusions 
Feeding y/d® Feline for 6-months resulted in a significant decline in TT4 concentration 
without adverse effects.  Compared with other treatment modalities for feline hyperthyroidism, 
feeding y/d® Feline did not result in a significant decline in GFR, did result in a significant 
decrease in SCr, and had no change in EMD.   In addition,  there is evidence that serum SDMA 
may be a better marker for GFR than SCr in hyperthyroid cats. 
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 Tables 
Table 3.1 TT4 concentrations over time as measured by CLEIA 
CLEIA TT4 Concentrations (nmol/L) – Reference Interval 10-45 nmol/L 
Patient Baseline 1-month 2-month 3-months 6-month 
1 436 79.7 58.9 48.6 55 
2 236 265 112 85.2 59 
3 128 56.1 41.8 51.2 39.8 
4 66.8 32.3 18.8 46.7 33.8 
5 426 56.1 54.7 73 78.8 
6 421 118 69.5 136 176 
7 62.3 19.7 21.1 11 19.1 
8 72.6 44.3 39.1 42.7 46.9 
9 149 46.9 46.3 57.7 72.6 
10 236 71.6 57 66.5 54.4 
11 90.1 42.9 37.8 62.2 67.7 
12 82 45.3 46 52.1 43.2 
13 136 38.2 39.7 34.8 54 
14 185 39.7 64.1 86.1 64.2 
15 56.3 60 81.6 54.6 43 
Mean 185.54 67.72 52.56 60.56 60.5 
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Table 3.2 Thyroid to zygomatic salivary gland ratios 
 Thyroid to Zygomatic Salivary Gland Ratio 
Case 
No. 
Right Left 
1 11:1 39.7:1 
2 19.4:1 5.7:1 
3 3.78:1 1.43:1 
4 5.66:1 1.88:1 
5 45.75:1 17.04:1 
6 47.23:1 2.99:1 
7 2.19:1 6.08:1 
8 0.84:1 4.39:1 
9 2.33:1 10.45:1 
10 5.19:1 33.26:1 
11 7.45:1 4.2:1 
12 3.24:1 4.02:1 
13 No uptake 13.12:1 
14 3.05:1 7.65:1 
15 3.91:1 3.42:1 
Mean 11.5:1 10.36:1 
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Table 3.3  Variables evaluated before, 1, 3, and 6-months after treatment: body weight, 
USG, UGGTC, ERD, SBP, EMD and total thyroid volume 
 Initial 1-Month 3-Month 6-Month 
Body weight 
(kg) 
4.13 (2.78-7.4) 4.21 (2.83-7.12) 4.23 (3.00-7.17) 4.10 (2.97-6.76) 
USG  1.025 (1.012-
1.051) 
1.027 (1.011-
1.061) 
1.022 (1.008-
1.061) 
1.024 (1.012-
1.057) 
UGGTC 0.43 (0.2-1.3) 0.29 (0.1-0.5) 0.34 (0.1-0.8) 0.30 (0.1-0.9) 
ERD 1 (0-2) 0.8 (0-2) 0.93 (0-2) 0.67 (0-2) 
SBP (mmHg) 156 (125-190) 155 (115-200) 154 (120-190) 156 (120-195) 
Right EMD 
(cm)* 
1.55 (1.2-2.03) n/a n/a 1.56 (1.07-2.15) 
Left EMD 
(cm)* 
1.56 (1.2-2.01) n/a n/a 1.62 (1.05-2.09) 
Total Thyroid 
Volume 
(mm3)* 
369 n/a n/a 281 
Data are listed as mean and (range) values.   
The ERD values were scored as follows; negative = 0, low positive = 1, medium positive = 2, 
high positive = 3 
*Not all cats had all measurements available for EMD or thyroid gland volume 
calculations, the existing data was used in the analysis 
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Table 3.4 Michigan State University (MSU) thyroid function panel results   
 TT4 (nmol/L) TT3 (nmol/L) fT4ED (pmol/L) fT3 (pmol/L) TSH (mU/L) 
Case 
No. 
Initial 6 
Month 
Initial 6 
Month 
Initial 6 
Month 
Initial 6 
Month 
Initial 6 
Month 
1 >156 54 4.1 2.6 >128 35 10.8 5.7 0 8 
2 >156 59 >4.7 1.8 >128 46 9.6 5 0 0 
3 95 48 1.4 1.1 105 46 4.2 2.1 9 0 
4 73 40 1.5 1.4 53 43 2.4 2 0 0 
5 >156 68 4 1.9 >128 60 9.6 2.4 0 0 
6 >156 125 3.7 2.9 >128 >128 17.4 5 9 0 
7 79 18 0.9 0.4 69 27 1.2 1 8 0 
8 50 47 1.1 0.8 64 35 2.3 1.8 0 0 
9 101 63 2.5 2 104 55 6.8 4.3 0 0 
10 >156 56 3.1 2.2 >128 59 8.4 4.8 0 0 
11 77 59 0.9 0.8 73 49 1.8 2.2 0 0 
12 64 33 1 0.7 74 44 3.1 1.2 0 0 
13 96 60 2 1.4 >128 63 2.6 3.2 0 7 
14 116 79 1.6 1.9 110 57 2.7 5.4 0 0 
15 67 58 1.1 1.3 42 45 3.3 2.7 0 0 
Mean* 106.9 57.8 2.25 1.55 97.87 52.87 5.75 3.25 1.73 1 
Reference intervals: TT4 = 10-55 nmol/L, TT3 = 0.6-1.4 nmol/L, fT4ED = 10-50 pmol/L, fT3 
= 1.5-6.0 pmol/L, TSH = 0-21mU/L. 
*For mean calculations: TT4 values >156, a value of 157 was used, TT3 values >4.7, a value 
of 4.8 was used, and fT4ED values >128, a value of 129 was used. 
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Table 3.5 Variables evaluated before and 6-months after treatment: CLEIA TT4 
concentration, GFR, SCr concentration, and serum SDMA concentration  
 TT4 (nmol/L) GFR 
(ml/min/kg) 
SCr (mg/dl) SDMA (µg/dl) UPC 
Case No. Initial 6 
Months 
Initial 6 
Months 
Initial 6 
Months 
Initial 6 
Months 
Initial 6 
Months 
1 436 55 3.14 3.27 1.4 1.4 27 25 0.4 0.5 
2 236 59 1.62 1.72 0.6 0.9 10 10 1.3 0.3 
3 128 39.8 1.7 2.18 1.9 1.5 23 19 0.5 0.5 
4 66.8 33.8 3.03 2 1.1 0.8 8 8 0.3 0.5 
5 426 78.8 2.45 2.54 1.1 1.5 17 23 0.4 0.4 
6 421 176 2.64 2.64 0.6 0.4 11 10 0.3 0.4 
7 62.3 19.1 3.05 3.01 2 1.2 15 14 0.2 0.3 
8 72.6 46.9 1.77 1.57 1.2 0.9 9 8 0.3 0.3 
9 149 72.6 1.3 1.18 0.7 0.7 7 6 0.7 0.6 
10 236 54.4 1.98 2.27 0.6 0.8 10 8 0.4 0.4 
11 90.1 67.7 3.31 2.42 0.9 0.8 13 13 0.3 0.8 
12 82 43.2 2.65 2.64 1.2 0.7 13 10 0.3 0.2 
13 136 54 n/a* 2.13 1.1 0.8 9 9 0.4 0.3 
14 185 64.2 1.86 1.61 1.1 0.7 6 9 0.1 0.2 
15 56.3 43 1.9 2.7 1.1 0.9 9 12 0.2 0.2 
Mean 
(median) 
185.5 
(136) 
60.5 
(54.4) 
2.31 2.26 1.10 0.93 12.46 12.26 0.41 0.39 
SD 138.0 35.5 0.66 0.57 0.42 0.32 5.93 5.71 0.28 0.16 
p-value  < 0.001  0.71  < 0.05  0.41  0.74 
Reference intervals: TT4 = 10-45 nmol/L; SCr = 0.8-2.1 mg/dl; serum SDMA <14 µg/dl; 
UPC <0.4 
p-values: calculated to compare difference between baseline and 6-month post-treatment 
values, with significance considered p ≤ 0.05. 
*Initial GFR measurement for cat 13 was measured twice on two different occasions and 
each time found to be >10 ml/min/kg.  This value is significantly higher than any published 
reference interval, and was therefore removed from the statistical analysis. 
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 Footnotes 
a.  Immulite Chemiluminescent enzyme immunoassay, Siemens Healthcare, Erlangen, Germany. 
b.  Michigan State University Diagnostic Center for Population and Animal Health, Lansing, MI. 
c.  Idexx Laboratories, Westbrook, Maine. 
d.  HESKA Corporation, Loveland, CO. 
e.  Ultrasonic Doppler Flow Detector, Parks Medical Electronics Inc, Aloha, OR. 
f.  Bili Labstix, Bayer Healthcare LLC., Morristown, NJ. 
g.  Hitachi 911, Roche Diagnostics, Indianapolis, IN. 
h.  Ascend Laboratories, LLC, Montvale, NJ. 
i.  SAS, SAS Institute Inc, Cary, NC. 
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Appendix A - Abbreviations 
99mTc-DTPA 9mTc-labeled diethylenetriaminepentaacetic acid  
CLEIA Chemiluminescent enzyme immunoassay 
CKD  Chronic kidney disease 
CBC  Complete blood count 
EMD  Epaxial muscle diameter 
EDTA   Ethylenediaminetetraacetic acid 
ERD  Semi-quantitative feline specific albuminuria assay 
fT4  Free thyroxine 
fT4ED  Free thyroxine by equilibrium dialysis 
fT3  Free triiodothyronine 
GGT  Gamma-glutamyl transpeptidase 
GFR  Glomerular filtration rate 
KSU-VHC Kansas State University-Veterinary Health Center 
131I  Radioiodine 
MSU  Michigan State University 
mCi  Milicuries 
SCr  Serum creatinine 
SDMA  Serum symmetrical dimethyl arginine 
SD  Standard deviation 
SBP  Systolic blood pressure 
TT3  Total triiodothyronine 
TSH  Thyroid stimulating hormone 
T4  Thyroxine 
TT4  Total thyroxine 
T3  Triiodothyronine 
UAC  Urine albumin to creatinine ratio 
UPC  Urine protein to creatinine ratio 
UGGTC Urine gamma-glutamyl transpeptidase to creatinine ratio 
